<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-04-09</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38590028/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Multifeature quantitative motor assessment of upper limb ataxia including drawing and reaching</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38590028-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    OBJECTIVE: Voluntary upper limb movements are an ecologically important yet insufficiently explored digital-motor outcome domain for trials in degenerative ataxia. We extended and validated the trial-ready quantitative motor assessment battery &ldquo;Q-Motor&rdquo; for upper limb movements with clinician-reported, patient-focused, and performance outcomes of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38590938/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38590938-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone <a href="https://bit.ly/3SSPX1C">https://bit.ly/3SSPX1C</a>. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592184/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Predictors of 2-Year Post-Discharge Mortality in Hospitalized Older Patients</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592184-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: PA, frailty, and underweight at hospital admission should be considered when evaluating long-term survival prognosis, establishing risk profiles, and developing personalized care pathways in acute hospital care of older &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592440/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">From the Assessment Section of the German Society for Orthopedics and Trauma Surgery in collaboration with the German Society for Neuroscientific Assessment (DGNB) : Assessment recommendations for musculoskeletal injury consequences in private accident insurance</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592440-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592485/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Pulse oximetry signal loss during hypoxic episodes in preterm infants receiving automated oxygen control</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592485-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The aim of this study was to analyze signal loss (SL) resulting from low signal quality of pulse oximetry-derived hemoglobin oxygen saturation (SpO(2)) measurements during prolonged hypoxemic episodes (pHE) in very preterm infants receiving automatic oxygen control (AOC). We did a post hoc analysis of a randomized crossover study of AOC, programmed to set FiO(2) to &ldquo;back-up FiO(2)&rdquo; during SL. In 24 preterm infants (median (interquartile range)) gestational age 25.3 (24.6 to 25.6) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592542/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses&#39; Health Studies</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592542-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Recreational physical activity was associated with lower breast cancer risk in both pre- and postmenopausal women, supporting recreational physical activity as an accessible, modifiable exposure associated with reduced breast cancer risk regardless of menopausal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38592668/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Odontoid Fracture with Accompanying Severe Atlantoaxial Instability in Elderly Patients-Analysis of Treatment, Adverse Events, and Outcome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38592668-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    (1) Background: In elderly patients with type II odontoid fractures, accompanying severe atlantoaxial instability (AAI) is discussed as a marker possibly warranting more aggressive surgical therapy. This study aimed to characterize adverse events as well as the radiological and functional outcomes of surgical vs. conservative therapy in patients with odontoid fracture and AAI. (2) Methods: Patients aged 65 years and older with type II odontoid fracture and AAI treated were included. AAI &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8SSiC24E">给欧洲人发邮件时，我会把在美国会省掉的开头结尾的嘘寒问暖客套话加上。因为我想毕竟他们是欧洲人，不是美国人。这让我想起了Succession里Gerri说的，他们（欧...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8ssic24e/">
    
    
    
    
    
      
    
    给欧洲人发邮件时，我会把在美国会省掉的开头结尾的嘘寒问暖客套话加上。因为我想毕竟他们是欧洲人，不是美国人。这让我想起了Succession里Gerri说的，他们（欧洲人）是在全民免费医疗、高福利的阳光下长大的；而我们（美国人）是在狼群里长大的。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->美国·旧金山 (City of San Francisco)<!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8TV44LRV">关爱自己，从正视自己的精神疾患开始。我讲过几次我很喜欢看Amy Schumer主演的喜剧Life &amp; Beth。该剧第二季全季已在Hulu播出，我看到了第4集。我觉得第二季比第...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8tv44lrv/">
    
    
    
    
    
      
    
    关爱自己，从正视自己的精神疾患开始。我讲过几次我很喜欢看Amy Schumer主演的喜剧Life &amp; Beth。该剧第二季全季已在Hulu播出，我看到了第4集。我觉得第二季比第一季更有趣。虽然这部电视剧以喜剧形式展现了很多成年人的挣扎，但归根结底这些挣扎大多来自于童年时的trauma（精神创伤），尤其是被bully（霸凌）的经历。更重要的是，这一季突出了ASD（自闭症）对患者自己和家人的巨大影响，这更像是Amy Schumer利用自己的平台推广的一项公益项目。<!-- raw HTML omitted --><!-- raw HTML omitted -->这些年，在很多发达国家，普通人群对于精神疾病的正视程度越来越高。在美国，每年5月是Mental Health Awareness Month（精神健康公益月）。去年5月，Biden政府专门邀 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8UqCd3zb">ai无法取代人类的证据有了 - 转发 @名场面All:&amp;ensp;好狂野的动画…… 好放肆的剧情…… 名场面All的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8uqcd3zb/">
    
    
    
    
    
      
    
    ai无法取代人类的证据有了<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@名场面All<!-- raw HTML omitted -->: 好狂野的动画…… 好放肆的剧情…… <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->名场面All的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax2.sinaimg.cn/orj480/007ad9bhly1hoh1n57fmq">https://tvax2.sinaimg.cn/orj480/007ad9bhly1hoh1n57fmq</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8XXaCUAh">太明媚了，适合拯救我这种阴暗批[春游家族] - 转发 @Korea私服集:&amp;ensp;宋雨琦 INS更新🍃🎞️ [图片][图片][图片][图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8xxacuah/">
    
    
    
    
    
      
    
    太明媚了，适合拯救我这种阴暗批<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@Korea私服集<!-- raw HTML omitted -->: 宋雨琦 INS更新🍃🎞️ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8SUM3fvS">错的不是我，是这个世界👿👿👿 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8sum3fvs/">
    
    
    
    
    
      
    
    错的不是我，是这个世界👿👿👿 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8TNYn6Vz">#微博头像挂件# 我正在使用“感恩节”头像挂件，你也快戴上吧！ 头像挂件：感恩节</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8tnyn6vz/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->#微博头像挂件#<!-- raw HTML omitted --><!-- raw HTML omitted --> 我正在使用“感恩节”头像挂件，你也快戴上吧！ <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_web_default.png%22">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_web_default.png&quot;</a> referrerpolicy=&ldquo;no-referrer&rdquo; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8TOXAlwh">感觉这季节出门需要俩口罩了，室外外科口罩，室内N95[二哈]👿</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8toxalwh/">
    
    
    
    
    
      
    
    感觉这季节出门需要俩口罩了，室外外科口罩，室内N95<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->👿  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8VZAhSFe">听到一个建议：座子还棋头下两日制</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8vzahsfe/">
    
    
    
    
    
      
    
    听到一个建议：<!-- raw HTML omitted -->座子还棋头下两日制  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8W8ElCD4">感谢大自然的馈赠 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8w8elcd4/">
    
    
    
    
    
      
    
    感谢大自然的馈赠 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8XjK1L1n">教大老爷：shrimp他：睡pu，玩pu</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8xjk1l1n/">
    
    
    
    
    
      
    
    教大老爷：shrimp<!-- raw HTML omitted -->他：睡pu，玩pu  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Ua52KIZ">繼披薩、煎餃、鹽麵包後的新研發方向[二哈] - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#久保史绪里手机博# 2024.04.09 11:27「嘿嘿嘿」想做日式菜饭！想吃！想变得健康...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8ua52kiz/">
    
    
    
    
    
      
    
    繼披薩、煎餃、鹽麵包後的新研發方向<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/tim">https://n.sinaimg.cn/photo/5213b46e/20180926/tim</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8VQkeZ21">紗月緒 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8vqkez21/">
    
    
    
    
    
      
    
    紗月緒 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8VYXjMQi">日飯搶先開內封生寫，久保真好看！ [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8vyxjmqi/">
    
    
    
    
    
      
    
    日飯搶先開內封生寫，久保真好看！ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Ydq0gPN">转发微博 - 转发 @井上诶嘿子:&amp;ensp;民国谍战电影女二号 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8ydq0gpn/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@井上诶嘿子<!-- raw HTML omitted -->: 民国谍战电影女二号 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8Ts13lcF">井山：一直盯着棋盘实在是太累了，前几天去看了看樱花。樱花几乎盛开，人也非常多#围棋#围棋 [图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8ts13lcf/">
    
    
    
    
    
      
    
    井山：一直盯着棋盘实在是太累了，前几天去看了看樱花。<!-- raw HTML omitted -->樱花几乎盛开，人也非常多<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8TH6yMba">久保史绪里#久保史绪里手机博# 2024.04.09 11:27「嘿嘿嘿」想做日式菜饭！想吃！想变得健康！！！！！！！！！！！！</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8th6ymba/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WiuhBwm">久保史绪里via.eagles_shop [图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wiuhbwm/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.eagles_shop <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hokq9xhr">https://tvax1.sinaimg.cn/large/006z6nxLgy1hokq9xhr</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WiyFaen">久保史绪里#久保史绪里手机博# 2024.04.09 18:49「噗」最近立马就肚子饿了啊。但蔬菜却怎么都煮不熟啊。明明盖上了盖子诶〜肚子饿了啊、、、</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wiyfaen/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8WnY6DTq">久保史绪里#久保史绪里手机博# 2024.04.09 18:52「啪」吃蔬菜。最近都没怎么吃蔬菜要吃好多好多好多蔬菜。你喜欢什么蔬菜啊啊！！</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8wny6dtq/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpage=1&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8VPW0ag5">柯洁#2024lg杯选拔赛##赛事预告# 柯洁九段执黑255手中盘胜李维清九段。继续加油！[加油][加油][加油][赢牛奶][赢牛奶][赢牛奶] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8vpw0ag5/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->柯洁<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#2024 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8WwBrX3s">柯洁#2024lg杯选拔赛##赛事预告# 第29届LG杯世界围棋棋王战中国代表选拔赛第一阶段第二轮将于明天中午十二点半在浙江衢州南孔观堂酒店进行，柯洁九段对阵好朋友...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8wwbrx3s/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->柯洁<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1761134909119123456">量子位发布了想法: 带领团队开发ChatExcel、ChatLaw的北京大学深圳研究生院助理教授袁粒 确认参与 #中国AIGC产业峰会 ！🔥&lt;br&gt;&lt;br&gt;袁粒，北京大学博士生导师、...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1761134909119123456/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691499895">量子位发表了文章: OpenAI创始大神手搓千行C代码训练GPT，附PyTorch迁移教程</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691499895/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691508465">量子位发表了文章: 北大开源最强aiXcoder-7B代码大模型！聚焦真实开发场景，专为企业私有部署设计</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691508465/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691509851">量子位发表了文章: 香港大模型公司Weitu AI首秀，打造多模态Native的技术和产品</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691509851/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691510637">量子位发表了文章: GPT-4一眼看穿论文会不会撤稿：7000篇实测准确率高达95%｜人大浙大</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691510637/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691543378">量子位发表了文章: 刚刚，又有20亿巨款砸向AI，产业场景里的AGI</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691543378/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691546846">量子位发表了文章: WPS 365全新发布，开启企业一站式AI办公</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-09</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691546846/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240408180459&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240408180459-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240409180647&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240409180647-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240408180525&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240408180525-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584594/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240409180657&amp;v=2.18.0.post9&#43;e462414">Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240409180657-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital pathology and deep learning to predict responses to immunochemotherapy in patients with DLBCL. We retrospectively collected 251 slide images from 216 DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584857/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Usage Behaviour and Adoption Criteria for Mobile Health Solutions in Patients with Chronic Diseases in Gastroenterology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584857-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Mobile Health (mHealth) applications allow for new possibilities and opportunities in patient care. Their potential throughout the whole patient journey is undisputed. However, the eventual adoption by patients depends on their acceptance of and motivation to use mHealth applications as well as their adherence. Therefore, we investigated the motivation and drivers of acceptance for mHealth and developed an adapted model of the Unified Theory of Acceptance and Use of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38584883/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38584883-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: With excellent long-term treatment outcomes and minimal associated toxicities, our results showed that LDR brachytherapy can be an effective treatment of choice in younger &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38585372/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38585372-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TV(MR+FET) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38586081/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter &lt;em&gt;SMILE&lt;/em&gt; phase II trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38586081-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38586301/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38586301-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587186/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587186-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). ARID1A is accumulated at DSBs after DNA damage and regulates chromatin loops formation by recruiting RAD21 and CTCF &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587213/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Evolution of Pyoderma Gangrenosum</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587213-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587218/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">unDOCumented - On Becoming an Undocumented Doctor in the United States</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587218-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587233/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587233-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Empagliflozin after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Empagliflozin after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587239/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587239-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587239/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587239-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587241/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587241-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587241/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587241-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587247/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587247-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587247/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587247-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Shooting the Messenger to Treat Hypertriglyceridemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Shooting the Messenger to Treat Hypertriglyceridemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587249/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587249-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587249/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587249-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587250/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587250-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587250/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587250-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587253/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587253-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587253/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587253-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587254/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587254-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587254/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587254-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587255/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Routine Beta-Blockers in Secondary Prevention - On Injured Reserve</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587255-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587255/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Routine Beta-Blockers in Secondary Prevention - On Injured Reserve</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587255-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587261/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240408180508&amp;v=2.18.0.post9&#43;e462414">Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587261-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240408180508-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis and a small aortic annulus who underwent TAVR, a self-expanding supraannular valve was noninferior to a balloon-expandable valve with respect to clinical outcomes and was superior with respect to bioprosthetic-valve dysfunction through 12 months. (Funded by Medtronic; SMART ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587261/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587261-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis and a small aortic annulus who underwent TAVR, a self-expanding supraannular valve was noninferior to a balloon-expandable valve with respect to clinical outcomes and was superior with respect to bioprosthetic-valve dysfunction through 12 months. (Funded by Medtronic; SMART ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587317/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587317-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Microsatellite-unstable (MSI) cancers require WRN helicase to resolve replication stress due to expanded DNA (TA)n-dinucleotide repeats. WRN is a promising synthetic lethal target for MSI tumours, and WRN inhibitors are in development. Here, we used CRISPR-Cas9 base editing to map WRN residues critical for MSI cells, validating the helicase domain as the primary drug target. Fragment-based screening led to the development of potent and highly selective WRN helicase covalent inhibitors. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587386/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587386-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This protocol details the propagation and passaging of human iPSCs and their differentiation into osteoclasts. First, iPSCs are dissociated into a single-cell suspension for further use in embryoid body induction. Following mesodermal induction, embryoid bodies undergo hematopoietic differentiation, producing a floating hematopoietic cell population. Subsequently, the harvested hematopoietic cells undergo a macrophage colony-stimulating factor maturation step and, finally, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587564/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">The role of coronary artery disease in lung transplantation: a propensity-matched analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587564-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In this cohort, relevant CAD was not associated with worse outcomes and should therefore not be considered a contraindication for LuTx. Nonetheless, cardiovascular events in CAD patients highlight the necessity of control of cardiovascular risk factors and a structured cardiac &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587632/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Congenital diaphragmatic hernia : Imaging-from diagnosis to aftercare</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587632-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    STANDARD RADIOLOGICAL METHODS: Fetal: Ultrasound and magnetic resonance imaging (MRI); postnatal: conventional X‑ray diagnostics, computed tomography (CT) and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587854/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240408180554&amp;v=2.18.0.post9&#43;e462414">Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587854-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240408180554-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND RELEVANCE: This nonrandomized controlled trial demonstrated effectiveness of newborn screening for infants with SMA in the real-world setting. Functional outcomes and thus the response to treatment were significantly better in the newborn screening cohort compared to the unscreened clinical symptom onset &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38587995/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38587995-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with STEMI or very-high-risk NSTEMI and multivessel coronary artery disease, FFR-guided complete revascularization was not shown to result in a lower risk of a composite of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only PCI at 4.8 years. (Funded by the Swedish Research Council and others; FULL REVASC ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588006/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588006-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588008/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Another Early Win for TAVI in Low-Risk Patients</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588008-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588025/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240409180652&amp;v=2.18.0.post9&#43;e462414">Transcatheter or Surgical Treatment of Aortic-Valve Stenosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588025-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240409180652-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with severe aortic stenosis at low or intermediate surgical risk, TAVI was noninferior to SAVR with respect to death from any cause or stroke at 1 year. (Funded by the German Center for Cardiovascular Research and the German Heart Foundation; DEDICATE-DZHK6 ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240409180636&amp;v=2.18.0.post9&#43;e462414">Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588489-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240409180636-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL). Although both presentations are similar in morphology and immunophenotype, molecular studies are virtually restricted to BCP-ALL so far. The lack of molecular studies on BCP-LBL is due to its rarity and the restriction to small, mostly &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588654/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Indicated Stress Prevention Addressing Adolescents with High Stress Levels Based on Principles of Acceptance and Commitment Therapy: A Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588654-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Indicated prevention, especially when based on the principles of ACT and CBT, seems efficient in significantly decreasing stress in adolescents with increased &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588693/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">The value of contrast-enhanced ultrasound in percutaneous biopsy of retroperitoneal masses</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588693-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Percutaneous CEUS-guided biopsy is a safe procedure with a high diagnostic yield and a low complication &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588756/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">The fentanyl-specific antibody FenAb024 can shield against carfentanil effects</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588756-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The surge in opioid-related deaths, driven predominantly by fentanyl and its synthetic derivatives, has become a critical public health concern, which is particularly evident in the United States. While the situation is less severe in Europe, the European Monitoring Centre for Drugs and Drug Addiction reports a rise in drug overdose deaths, with emerging concerns about the impact of fentanyl-related molecules. Synthetic opioids, initially designed for medical use, have infiltrated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588862/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Reply to: Kavsak et al. The clinical chemistry score (CCS) achieves the highest efficacy when assessed with the 99% sensitivity benchmark for myocardial infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588862-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588880/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240409180657&amp;v=2.18.0.post9&#43;e462414">INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and Young Adults</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588880-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240409180657-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588929/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588929-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588930/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588930-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38588993/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">An International Multicenter Cohort Study on Implantable Cardioverter Defibrillators for the Treatment of Symptomatic Children with Catecholaminergic Polymorphic Ventricular Tachycardia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38588993-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: SCD events occurred only in the no ICD group, in those not on optimal medical therapy. ICD patients had a high risk of appropriate and inappropriate shocks, which may be reduced with appropriate device programming. Severe ICD complications were common and risks versus benefits of ICDs need to be &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589007/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20240409180640&amp;v=2.18.0.post9&#43;e462414">A muti-modal feature fusion method based on deep learning for predicting immunotherapy response</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589007-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20240409180640-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Immune checkpoint therapy (ICT) has greatly improved the survival of cancer patients in the past few years, but only a small number of patients respond to ICT. To predict ICT response, we developed a multi-modal feature fusion model based on deep learning (MFMDL). This model utilizes graph neural networks to map gene-gene relationships in gene networks to low dimensional vector spaces, and then fuses biological pathway features and immune cell infiltration features to make robust predictions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589480/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Exploring the microbial savanna: predator-prey interactions in the soil</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589480-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589601/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Maternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother-child pairs</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589601-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother-child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between different MDM (any MDM, gestational diabetes mellitus (GDM) and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589615/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Atmospheric pressure field desorption-trapped ion mobility-mass spectrometry coupling</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589615-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    While field ionization (FI) and field desorption (FD) are established soft vacuum ionization methods in mass spectrometry (MS), the technique of atmospheric pressure field desorption (APFD) has only recently been added to the repertoire. Similar to FI and FD, APFD can yield both positive even-electron ions of highly polar or ionic compounds and positive molecular ions, M^(+•), e.g., of polycyclic aromatic compounds. Thus, a dedicated APFD source assembly has been constructed and demonstrated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589793/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&amp;fc=20220814223158&amp;ff=20240409180647&amp;v=2.18.0.post9&#43;e462414">Deep learning-based image annotation for leukocyte segmentation and classification of blood cell morphology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589793-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1byxlwg-5hn0-qdlgzypdfla2uwghgngzgereuo1rjn2aoaqxp-fc-20220814223158-ff-20240409180647-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The research focuses on the segmentation and classification of leukocytes, a crucial task in medical image analysis for diagnosing various diseases. The leukocyte dataset comprises four classes of images such as monocytes, lymphocytes, eosinophils, and neutrophils. Leukocyte segmentation is achieved through image processing techniques, including background subtraction, noise removal, and contouring. To get isolated leukocytes, background mask creation, Erythrocytes mask creation, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589856/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589856-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1-3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20-40% and recurrence rates are up to ~ 75%(4-6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589879/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Fasting upregulates the monocarboxylate transporter MCT1 at the rat blood-brain barrier through PPAR δ activation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589879-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Altogether, our study shows that fasting affects a selected set of BBB transporters which does not include the main drug efflux transporters. Moreover, we describe a previously unknown selective adaptive response of the brain vasculature to fasting which involves PPAR δ and is responsible for the up-regulation of MCT1 expression and activity. Our study opens new perspectives for the metabolic manipulation of the BBB in the healthy or diseased &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38589974/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240409180714&amp;v=2.18.0.post9&#43;e462414">Clinical profiles of adolescent personality pathology: a latent structure examination of the Semi-Structured Interview for Personality Functioning DSM-5 (STiP-5.1) in a help-seeking sample</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38589974-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240409180714-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: A complex model incorporating both dimensional and categorical components most adequately describes the latent structure of the STiP-5.1 in our adolescent sample. We conclude that Criterion A provides clinically useful information beyond severity (as a dimensional continuum) alone, and that the hybrid model found for personality functioning in our sample warrants further attention. Findings can help to parse out clinical heterogeneity in personality pathology in adolescents, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8JKrspzK">Sam’s Chowder，SF特色佳肴Cioppino特别美味。这里是美景&#43;美食。这些年，我与我认识的很多hiring manager和recruiter以及我自己的career coach聊天，我问他们湾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8jkrspzk/">
    
    
    
    
    
      
    
    Sam’s Chowder，SF特色佳肴Cioppino特别美味。这里是美景+美食。这些年，我与我认识的很多hiring manager和recruiter以及我自己的career coach聊天，我问他们湾区/硅谷最好的是什么，他们都不约而同地回答talent pool。我很多东海岸毕业的同事都愿意搬到这里。这让我想起了2010年电影The Social Network，影片中Saverin对在Cambridge冰天雪地中的Zuckerberg说，你必须要到这里来创业，这里太不一样了。然后Zuckerberg一来他们就跳进了户外游泳池。四季恒温+太平洋大洋景色是创业者天堂。 <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_location_default.png%22">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_location_default.png&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/O8Ky9p88i">这孩子可以，有前途！ - 转发 @王凯伦KW:&amp;ensp;没想到，刚买的书我还没翻，被我8岁的儿子在飞机上看完了。整个清明假期他翻了不下三遍，边看边哈哈大笑，还跟我...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-o8ky9p88i/">
    
    
    
    
    
      
    
    这孩子可以，有前途！<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@王凯伦KW<!-- raw HTML omitted -->: 没想到，刚买的书我还没翻，被我8岁的儿子在飞机上看完了。整个清明假期他翻了不下三遍，边看边哈哈大笑，还跟我玩小说内容问答，可见是真爱。我昨晚趁娃睡着终于熬夜看完了，脑子里不由自主地回荡着舌尖上的配乐和配音。太好看了 <!-- raw HTML omitted -->@马伯庸<!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/731202f7gy1hoj4lh6uf7j22c03401ky.jpg%22">https://tvax1.sinaimg.cn/large/731202f7gy1hoj4lh6uf7j22c03401ky.jpg&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/O8M0byAVR">飞哥难得出书，我随个份子[打call]给中奖的朋友一人加送一本《食南之徒》 - 转发 @月宅fei:&amp;ensp;各位亲人，今天是不是也没什么上班的热情？那我正好跟大家说个...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-o8m0byavr/">
    
    
    
    
    
      
    
    飞哥难得出书，我随个份子<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->给中奖的朋友一人加送一本《食南之徒》<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@月宅fei<!-- raw HTML omitted -->: 各位亲人，今天是不是也没什么上班的热情？那我正好跟大家说个事儿~<!-- raw HTML omitted -->我的新书，科幻小说《重启黎明》这个月出版了。主要是讲在几年后的未来某一天，天上突然出现了大十字，地上蹦出来许多超能力者，眼瞅着全世界都不大妙，这时候有一个在美国出差、平平无奇的中国妇女站了出来，为了回国与家人团聚，一路带着同事和路上捡到（……）的队友们，杀穿了半个东海岸（好吧三分之一个），去给大魔王一 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8KlImb30">“我忘啦hhh”[苦涩][苦涩][苦涩]好可爱的狗[苦涩][苦涩][苦涩] - 转发 @白客万事屋:&amp;ensp;cucn201白客白客 Boss《早点才会赢》之开工小记📹祝大家周一快乐！ ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8klimb30/">
    
    
    
    
    
      
    
    “我忘啦hhh”<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;/s &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/O8Oz8x1XU">啊啊啊笑得 - 转发 @Wink-小狗:&amp;ensp;今天刷到别人的，怎么没有人玩这个梗？虽然我感觉过时了[坏笑] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-o8oz8x1xu/">
    
    
    
    
    
      
    
    啊啊啊笑得<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@Wink-小狗<!-- raw HTML omitted -->: 今天刷到别人的，怎么没有人玩这个梗？虽然我感觉过时了<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8NI5pLQU">咖啡加奥美拉唑，能不能精神着治了胃病[怒]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8ni5plqu/">
    
    
    
    
    
      
    
    咖啡加奥美拉唑，能不能精神着治了胃病<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8PWusSnI">想起了三十年前的事情</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8pwussni/">
    
    
    
    
    
      
    
    想起了三十年前的事情  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8OAeDEwV">头发，真的好长了 - 转发 @山下美月教会:&amp;ensp;山下美月 乃木坂46『夏桜』Music Video 山下美月教会的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8oaedewv/">
    
    
    
    
    
      
    
    头发，真的好长了<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@山下美月教会<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->山下美月<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->乃木坂46『夏桜』Music Video<!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:5020992972718092%22">https://video.weibo.com/show?fid=1034:5020992972718092&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Od69GgS">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#久保史绪里手机博# 2024.04.08 19:10「呜呼呼」是想努力的日子呢〜虽然天气不太稳定，但不要被这左右，聆听喜欢的...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8od69ggs/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/searc">https://m.weibo.cn/searc</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Od9AHED">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via. 緒行记ins 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8od9ahed/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via. 緒行记ins <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Ohemcxw">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via.乃木坂46 tiktok [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8ohemcxw/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.乃木坂46 tiktok &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hojov4ictij31ey1w0kjl.jpg%22">https://tvax1.sinaimg.cn/large/006z6nxLgy1hojov4ictij31ey1w0kjl.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Pwqtrld">原来当你说想要见一个人只要能说出口，她也会愿意见你怎么不是双向奔赴</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8pwqtrld/">
    
    
    
    
    
      
    
    原来当你说想要见一个人<!-- raw HTML omitted -->只要能说出口，她也会愿意见你<!-- raw HTML omitted -->怎么不是双向奔赴  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeAfMEf">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#久保史绪里手机博# 2024.04.08 21:03「呼呼呼」啊，我在看昨天的比赛哟昨天因为在工作没能看所以现在看。我最幸福...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qeafmef/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231">https://m.weibo.cn/search?containerid=231</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeDbZTv">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#shiorigram# .日复一日。现在喜欢的词语。我的喜欢的词语。没有哪一天是相同的，每天都是特别的日子，所以我也曾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qedbztv/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?">https://m.weibo.cn/search?</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeL7pmJ">st你真该死 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里久保酱最后的留言✉️💜为了各位读者，让她手写了信件哦。每一个词语都很温暖，是有着久保酱风格的留言😌给S...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qel7pmj/">
    
    
    
    
    
      
    
    st你真该死<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8QeNt58o">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#shiorigram# 这是Seventeen的最后一次拍摄的模样。请一定要看哦。🌷 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qent58o/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;am">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;am</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8Qey6cKx">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#久保史绪里手机博# 2024.04.08 21:02「呼呼呼」今天晚安了我要以自己的风格，去做我该做的事！会好好努力的哦〜晚...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8qey6ckx/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t">https://m.weibo.cn/search?containerid=231522type%3D1%26t</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Kbieqr1">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via.seventeenjp_mag ins [图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kbieqr1/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1hoj5q4j86bj30m80rs0ut.jpg%22">https://tvax4.sinaimg.cn/large/006z6nxLgy1hoj5q4j86bj30m80rs0ut.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8Kf49BFp">月緒 久保醬是ten使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kf49bfp/">
    
    
    
    
    
      
    
    月緒 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保醬是ten使的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/GixlonFUlx08dUUCPuEU010412000PYZ0E010.mp4?label=mp4_h">https://f.video.weibocdn.com/o0/GixlonFUlx08dUUCPuEU010412000PYZ0E010.mp4?label=mp4_h</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8KgQ50T5">正[太开心][太开心][太开心] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kgq50t5/">
    
    
    
    
    
      
    
    正<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8KVT3S8d">很可愛耶//@The_Notorious_vo1d:这张当写真集封面效果比较好 - 转发 @The_Notorious_vo1d:&amp;ensp;#山下美月# [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8kvt3s8d/">
    
    
    
    
    
      
    
    很可愛耶//<!-- raw HTML omitted -->@The_Notorious_vo1d<!-- raw HTML omitted -->:这张当写真集封面效果比较好<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@The_Notorious_vo1d<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted -->#山下美月#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8MmWAnLI">都是休息室的一灘白雪了[哈哈] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8mmwanli/">
    
    
    
    
    
      
    
    都是休息室的一灘白雪了<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8NES8rsb">嘟嘴 - 转发 @AyaTea:&amp;ensp;吉田绫乃#吉田绫乃クリスティー##吉田绫乃克莉丝蒂# 35单音番成员间合照 吉田绫乃克莉丝蒂部分via.乃木坂46 Tiktok [图片][图片][图...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8nes8rsb/">
    
    
    
    
    
      
    
    嘟嘴<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@AyaTea<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->吉田绫乃<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%90%89%E7%94%B0%E7%BB%AB%E4%25B">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%90%89%E7%94%B0%E7%BB%AB%E4%B</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8OqXeUEa">嘟嘴可愛，抿嘴更可愛[哈哈] - 转发 @IRON欧米伽:&amp;ensp;久保史绪里壁纸[送花花] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8oqxeuea/">
    
    
    
    
    
      
    
    嘟嘴可愛，抿嘴更可愛<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@IRON欧米伽<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defaul">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_defaul</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8MJjmgHm">【悲报】找借口安静，年初说好一周4篇左右就好，连载一搞开始被迫日更#围棋#围棋</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8mjjmghm/">
    
    
    
    
    
      
    
    【悲报】找借口安静，年初说好一周4篇左右就好，连载一搞开始被迫日更<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8NqwFegS">截止至4月4日的日本棋手多胜榜（不包括NHK杯和龙星战的战绩）排名的变动幅度根据3月22日的排名进行比较#围棋#围棋 [图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8nqwfegs/">
    
    
    
    
    
      
    
    截止至4月4日的日本棋手多胜榜（不包括NHK杯和龙星战的战绩）<!-- raw HTML omitted --><!-- raw HTML omitted -->排名的变动幅度根据3月22日的排名进行比较<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8NZnuFYJ">棋手战鹰1号的意义重大[二哈] [图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8nznufyj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->棋手战鹰<!-- raw HTML omitted --><!-- raw HTML omitted -->1号的意义重大<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8PbmEofW">发布了头条文章：《喜多文子：日本围棋界之母——日本围棋百大奠基人007》 #围棋# 围棋 喜多文子：日本围棋界之母——日本围棋百大奠基人007 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8pbmeofw/">
    
    
    
    
    
      
    
    发布了头条文章：《喜多文子：日本围棋界之母——日本围棋百大奠基人007》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8Jug0gar">久保史绪里via.seventeenjp_mag ins [图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8jug0gar/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1h">https://tvax4.sinaimg.cn/large/006z6nxLgy1h</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8MsdocSS">久保史绪里via.nogizaka_goods X2024年4月随机生写 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8msdocss/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.nogizaka_goods X<!-- raw HTML omitted -->2024年4月随机生写 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8N3e1SBJ">久保史绪里#久保史绪里手机博# 2024.04.08 19:10「呜呼呼」是想努力的日子呢〜虽然天气不太稳定，但不要被这左右，聆听喜欢的音乐，品尝喜欢的食物，喜欢的人则...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8n3e1sbj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8N7Ay8M3">久保史绪里via. 緒行记ins 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8n7ay8m3/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via. 緒行记ins <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/time">https://h5.sinaimg.cn/upload/2015/09/25/3/time</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8NP1DRf1">久保史绪里via.乃木坂46 tiktok [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8np1drf1/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.乃木坂46 tiktok <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006z6nxLgy1hoj">https://tvax3.sinaimg.cn/large/006z6nxLgy1hoj</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PCIyAiT">久保史绪里#久保史绪里手机博# 2024.04.08 21:02「呼呼呼」今天晚安了我要以自己的风格，去做我该做的事！会好好努力的哦〜晚安！感觉能时隔许久地睡得很沉！大...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pciyait/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;am">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;am</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PCSwYtM">久保史绪里#久保史绪里手机博# 2024.04.08 21:03「呼呼呼」啊，我在看昨天的比赛哟昨天因为在工作没能看所以现在看。我最幸福的时间。当然很想集中精神看啦…但...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pcswytm/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PD9h1La">久保史绪里#shiorigram# .日复一日。现在喜欢的词语。我的喜欢的词语。没有哪一天是相同的，每天都是特别的日子，所以我也曾想过，这样汇总成一个词语到底好不好...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pd9h1la/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%23shiorigram%23%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%23shiorigram%23&quot;</a>  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PJU7Afh">久保史绪里久保酱最后的留言✉️💜为了各位读者，让她手写了信件哦。每一个词语都很温暖，是有着久保酱风格的留言😌给Seventeen的各位读者约6年半以来，真的...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pju7afh/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保酱最后的留言✉️💜<!-- raw HTML omitted -->为了各位读者，让她手写了信件哦。每一个词语都很温暖，是有着久保酱风格的留言😌<!-- raw HTML omitted -->&lt;b &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8PK5dv6N">久保史绪里#shiorigram# 这是Seventeen的最后一次拍摄的模样。请一定要看哦。🌷 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8pk5dv6n/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8Oism1JF">柯洁 给好朋友过生日的柯柯～[送花花] - 转发 @杨楷文-:&amp;ensp;@连笑 20岁生日快乐🎂🎂 衢州 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8oism1jf/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->柯洁<!-- raw HTML omitted --><!-- raw HTML omitted --> 给好朋友过生日的柯柯～<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/O8OUR4sYe">柯洁#2024lg杯选拔赛##赛事预告# 第29届LG杯世界围棋棋王战中国代表选拔赛第一阶段将于4月9日、10日、12日中午十二点半在浙江衢州南孔观堂酒店进行，柯洁九段首...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-o8our4sye/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->柯洁<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1aZ421e79K">下冰雹的夜晚，跟狗闺蜜坐在村口聊天，这份友情千金难买哦</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1az421e79k/">
    
    
    
    
    
      
    
    下冰雹的夜晚，跟狗闺蜜坐在村口聊天，这份友情千金难买哦<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1Gx4y1Y7cJ">【直播回放】嘟嘟吃饭饭咯！ 2024年4月8日19点场</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1gx4y1y7cj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1KT421m7RT">陈翔六点半：令人崩溃的坦白局，还有什么是我不知道的</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1kt421m7rt/">
    
    
    
    
    
      
    
    当你的女朋友有秘密时&hellip;<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1om411z7Ln">我一定要拯救我哥哥！！！</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1om411z7ln/">
    
    
    
    
    
      
    
    -<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1yt421E7im">美食是相逢最好的理由，简简单单做个铁桶烤全羊！</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1yt421e7im/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1760620534143180801">量子位发布了想法: 金山办公副总裁姚冬 确认参与 &lt;a class=&#34;hash_tag&#34; href=&#34;https://www.zhihu.com/topic/27243576&#34; data-pin-topic=&#34;zhihu://topic/27243576/p...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1760620534143180801/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/pin/1760757887067172865">量子位发布了想法: 蚂蚁集团代码大模型CodeFuse负责人李建国 确认参与 #中国AIGC产业峰会 ！🔥&lt;br&gt;&lt;br&gt;李建国博士深耕机器学习、深度学习领域多年，在相关顶会...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-pin-1760757887067172865/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651930592/answer/3458734195">张敬信回答了问题: 请问如何在excel中自动生成每个字出现的次数？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651930592-answer-3458734195/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691083149">量子位发表了文章: 阿里刚开源32B大模型，我们立马测试了“弱智吧”</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691083149/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691250731">量子位发表了文章: “音乐版Sora”首批演示泄露，网友：比写《宫保鸡丁》的Suno好10倍</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691250731/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691258824">量子位发表了文章: 陶哲轩转发、菲尔兹奖得主领衔：AI正在颠覆数学家的工作方式 | 美国数学学会特刊</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691258824/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691264949">量子位发表了文章: 北大&amp;火山引擎夺冠！CLIC视频压缩挑战赛结果公布，中国团队表现亮眼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691264949/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/691268834">量子位发表了文章: 第一个能听懂人类语气的AI火了，网友：感觉在和真人交谈</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-08</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-691268834/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

